Interpretation of NCCN guidelines for hepatobiliary tumors V3 update in 2021  

作　　者：Lingxiao Xu Jun Zhou 

机构地区：[1]Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing,China

出　　处：《Hepatobiliary Surgery and Nutrition》2021年第5期682-685,共4页肝胆外科与营养（英文）

摘　　要：Interpretation of NCCN guidelines for hepatobiliary tumors V3 update in 2021(1).Hepatobiliary tumors are a general term for a large group of tumors,including liver cancer and biliary tract tumors.It is rare,highly aggressive and has a poor prognosis.Biliary tract tumors are highly heterogeneous,and the chemotherapy effect of unresectable tumors is poor.The objective response rate(ORR)of first-line chemotherapy is 20-30%,while ORR of second-line chemotherapy is only about 5%.As one of the most authoritative guidelines,NCCN proposed some new medical treatment recommendations,and these updates mainly focused on targeted therapy and immunotherapy,with relatively few updates on chemotherapy this year.

关 键 词：CHEMOTHERAPY NCCN TUMORS 

分 类 号：R73[医药卫生—肿瘤]